43 citations
,
January 2012 in “Biological Research”
This review discusses the embryonic origins and characteristics of various stem cell populations in the skin, but it provides no new experimental results.
15 citations
,
September 2007 in “Cell & tissue research/Cell and tissue research”
This study suggests that human embryonic stem cells may improve skin graft quality and functionality by enabling the identification and amplification of early ectodermal progenitors, pending confirmation from preclinical studies.
3 citations
,
August 2018 in “Stem cells international”
This study found that cultured hair follicle dermal cells support maintenance and potentially aid in the clinical application of pluripotent and haematopoietic stem cells.
8 citations
,
March 2015 in “International Journal of Oncology”
This study successfully established Tsc2-deficient embryonic stem cells from Eker rats and found these cells have distinct gene expression compared to non-mutant cells, which could help identify new therapeutic targets for TSC-related pathogenesis.
7 citations
,
March 2017 in “Experimental and Therapeutic Medicine”
This study found that human hair follicle-derived mesenchymal stem cells effectively maintained human embryonic stem cells in an undifferentiated state, comparable to mouse embryonic fibroblasts under standard conditions.
Human pluripotent stem cells have been used to create hair and skin, potentially offering a new solution for baldness. A user also mentioned starting finasteride but experiencing unexpected hair thinning.
Hair loss treatments still rely heavily on minoxidil, finasteride, and RU58841, with little innovation. Future treatments like stem cell therapy and RNA technology show promise but are not yet available.
Baldness is difficult to cure because current treatments like finasteride, dutasteride, and minoxidil only prevent hair shedding, and new developments are mostly ineffective. Botox shows potential in aiding skin regeneration and hair growth, but maintenance therapy with treatments like dutasteride and minoxidil may still be necessary.
Clinical studies by Dr. Barghouthi and Dr. Bloxham indicate that Verteporfin, when used with FUE and FUT hair transplantation methods, shows promise in hair follicle regeneration and minimal scarring due to its ability to inhibit Yes-associated protein (YAP). Microneedling at depths of 3-3.5mm, combined with Verteporfin, could potentially reactivate dormant follicles, although the optimal dosage and application method are still under investigation. Concerns remain about the DHT sensitivity of regenerated follicles, highlighting the need for further research to optimize trauma levels and Verteporfin concentrations to achieve effective and scar-free hair regeneration.
A permanent hair loss solution could involve reprogramming hair follicles to resist DHT using mRNA and siRNA. However, high costs, safety concerns, and the pharmaceutical industry's preference for ongoing treatments over one-time cures are major obstacles, with finasteride and minoxidil remaining standard treatments.